trending Market Intelligence /marketintelligence/en/news-insights/trending/q9PzGEUX3vj6jXW6X08yjg2 content esgSubNav
In This List

Repros Therapeutics likely to get negative EU opinion on hypogonadism drug

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Repros Therapeutics likely to get negative EU opinion on hypogonadism drug

Repros Therapeutics Inc. said its marketing application for enclomiphene in secondary hypogonadism is likely to receive a negative opinion in January 2018 from a European Medicines Agency committee.

The company received feedback regarding the forthcoming option, which will be issued by the Committee for Medicinal Products for Human Use, following an oral explanation.

The application was submitted by Renable Pharma Ltd., the company's U.K. unit.

Hypogonadism is a form of testosterone deficiency in adult males.

Allergan plc is in the process of acquiring Repros Therapeutics.